Browsing by Author "Anchalee Avihingsanon"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trialAnchalee Avihingsanon; Michael D. Hughes; Robert Salata; Catherine Godfrey; Sharlaa Badal-Faesen; Lerato Mohapi; E et al